Physician Spotlight

Dr. Kyle Bryan: Clinician and Sponsor Expertise

For nearly 25 years, James Kyle Bryan, M.D. has excelled in his career as a hematologist and oncologist. He now brings that experience, along with more than 20 years of drug development expertise with both pharmaceutical companies and global CROs, … Read More

The Patient: What It’s All About

In our work at Novella Clinical, we are rightfully focused on exceeding our customers’ expectations through innovative strategies, the quality of our deliverables, and achieving study goals on time and within budget. Our work is highly specialized and technical, and for … Read More

liquid biopsy technology

Harnessing Liquid Biopsies in Clinical Trials

Liquid biopsy technology is emerging as an enormously promising tool in the fight against cancer. Because it can detect changes in tumor genetics well before imaging reveals changes in growth, it has the potential to enable earlier intervention or treatment … Read More

immunotherapy clinical trials

Answering Your Toughest Immunotherapy Clinical Trials Questions

Small to midsize biopharmaceutical companies play significant, pioneering roles in innovating novel cancer therapeutics, particularly with the new wave of immunotherapeutic agents. They also have plenty of questions about clinical trial hurdles unique to this class of drugs — one … Read More

Oncology CRO

Novella Clinical Executive Named to PharmaVOICE 100

Since 2005, PharmaVOICE has honored innovative scientists through its PharmaVOICE 100. Scientists are selected for their contributions to the life sciences industry, specifically, their leadership, management, knowledge, and willingness to tackle major industry challenges – and the inspiration they bring. This … Read More

European Accelerated Regulatory Pathways Show Momentum

The European Medicines Agency (EMA) has launched a new expedited approval pathway similar to those available in the US to facilitate access to medicines for patients in the European Union (EU). European regulators introduced the PRIority MEdicines (PRIME) approval pathway … Read More